134150-01-9

Basic information

• Product Name: 4-Propylphenylboronic acid
• Synonyms: 4-PROPYLPHENYLBORIC ACID HPLC 98+%;4-n-Propylbenzeneboronic acid;4-Propylphenyboronic acid;(4-n-Propylphenyl)boronic acid;4-Propylphenylboronic acid (contains varying aMounts of anhydride);PropylPHenylboronic acid;AKOS BRN-0191;4-(PROPYL)BENZENEBORONIC ACID
• CAS NO: 134150-01-9
• Molecular Formula: C₉H₁₃BO₂
• Molecular Weight: 164.01
• EINECS: 1312995-182-4
• Product Categories: Boronic Acid series;Boronic acids;Aryl;Boronic Acids;Boronic Acids and Derivatives;Liquid crystal intermediates;blocks;BoronicAcids
• Mol File: 134150-01-9.mol

Chemical Properties

• Melting Point: 89-97 °C(lit.)
• Boiling Point: 299.1 °C at 760 mmHg
• Flash Point: 134.7 °C
• Appearance: White to off-white/Crystalline Powder
• Density: 1.05 g/cm³
• Vapor Pressure: 0.000542mmHg at 25°C
• Refractive Index: 1.516
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 8.71±0.10(Predicted)
• CAS DataBase Reference: 4-Propylphenylboronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Propylphenylboronic acid(134150-01-9)
• EPA Substance Registry System: 4-Propylphenylboronic acid(134150-01-9)

Safety Data

• Hazard Codes: Xi
• Safety Statements: 24/25
• WGK Germany: 3
• Hazardous Substances Data: 134150-01-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Propylphenylboronic acid is used as a reactant for the palladium/carbon-catalyzed Suzuki coupling reactions, which are crucial for the preparation of biologically and pharmacologically active molecules. This makes it an essential component in the development of new drugs and therapeutic agents.
Used in Chemical Synthesis:
4-Propylphenylboronic acid is used as an intermediate in the synthesis of liquid crystals, which have a wide range of applications in various industries, including electronics and display technology.
Used in Organic Chemistry:
4-Propylphenylboronic acid is utilized in the Suzuki reaction, a widely employed method in organic chemistry for the formation of carbon-carbon bonds, particularly in the synthesis of complex organic molecules and natural products.

InChI:InChI=1/C9H13BO2/c1-2-3-8-4-6-9(7-5-8)10(11)12/h4-7,11-12H,2-3H2,1H3

Upstream product

• 109-72-8 n-butyllithium 
• 5419-55-6 Triisopropyl borate 
• 588-93-2 p-bromo-n-propylbenzene 
• 121-43-7 Trimethyl borate 
• 126261-84-5 1-iodo-4-n-propylbenzene 
• 2696-84-6 4-propylaniline 
• 10342-59-3 1-nitro-4-propyl-benzene 
• 17763-80-3 para-nitrophenyl triflate 
• 1359844-00-0 pinacol(4-propylphenyl)boronate 
• 2114-36-5 1-bromopropylbenzene 

Downstream Products

• 10289-45-9 4-propyl-1,1'-biphenyl 
• 909709-42-8 2-fluoro-4-(4-propylphenyl)phenylboronic acid 

Relevant articles and documents

Design and synthesis of boronic acid inhibitors of endothelial lipase

Endothelial lipase (EL) and lipoprotein lipase (LPL) are homologous lipases that act on plasma lipoproteins. EL is predominantly a phospholipase and appears to be a key regulator of plasma HDL-C. LPL is mainly a triglyceride lipase regulating (V)LDL levels. The existing biological data indicate that inhibitors selective for EL over LPL should have anti-atherogenic activity, mainly through increasing plasma HDL-C levels. We report here the synthesis of alkyl, aryl, or acyl-substituted phenylboronic acids that inhibit EL. Many of the inhibitors evaluated proved to be nearly equally potent against both EL and LPL, but several exhibited moderate to good selectivity for EL.

Combinatorial organic materials research (COMR): design, synthesis and screening of a 225-membered materials library of liquid crystalline fluorinated p-quaterphenyls

The rapid solution phase synthesis of novel liquid crystalline materials is demonstrated by utilising combinatorial and parallel methods for the preparation of a library of 225 differently fluorinated 4,4?-dipropyl-p-quaterphenyl. Chemical diversity was i

COMPOUND HAVING TETRAHYDRONAPHTHALENE SKELETON AND LIQUID CRYSTAL COMPOSITION CONTAINING THE SAME

A tetrahydronaphthalene derivative represented by the general formula (I) and a liquid crystal composition containing the same. A compound represented by the general formula (I) shows superior liquid crystallinity and co-solubility with conventional liquid crystal compounds and compositions. Furthermore, addition of such a compound enables the threshold voltage to be significantly reduced with almost no deleterious effect on the responsiveness. In addition, a compound of the present invention can also be easily produced industrially, is colorless, and is chemically stable. Consequently, liquid crystal compositions containing such a compound are extremely useful as liquid crystals, and are particularly suitable for liquid crystal displays requiring a wide operating temperature range, low voltage driving and a high response speed.

Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin

Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin

Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

Heterocyclic compounds

The invention concerns pharmaceutically useful compounds of the formula I, in which A1, A2, A3, A4, B1, m, Ar, W, X, Y, Z and R1 have any of the meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel compounds possess endothelin receptor antagonist activity and are useful, for example, in the treatment of diseases or medical conditions in which elevated or abnormal levels of endothelin play a significant causative role. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.

THIENYL-, FURYL- AND PYRROLYL SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN

Thienyl-, furyl-and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl) furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN

Sulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided. The sulfonamides have formula I: STR1 in which Ar 1 is a 3-or 5-isoxazolyl and Ar. sup.2 is selected from among alkyl, including straight and branched chains, aromatic rings, fused aromatic rings and heterocyclic rings, including 5-membered heterocycles with one, two or more heteroatoms and fused ring analogs thereof and 6-membered rings with one, two or more heteroatoms and fused ring analogs thereof. Ar 2 is preferably thiophenyl, furyl, pyrrolyl, naphthyl, and phenyl. Compounds in which Ar. sup.1 is a 4-halo-substituted isoxazole are more active than the corresponding alkyl-substituted compound and compounds in which Ar 1 is substituted at this position with a higher alkyl tend to exhibit greater affinity for ET B receptors than the corresponding lower alkyl-substituted compound.

PHENYL SULFONAMIDE ENDOTHELIN ANTAGONISTS

Compounds of the formula STR1 inhibit the activity of endothelin. The symbols are defined as follows: R 1, R 2 and R. sup.3 are each independently(a) hydrogen, except that R. sup.1 is other than hydrogen;(b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z 1, Z 2 and Z. sup.3 ;(c) halo;(d) hydroxyl;(e) cyano; (f) nitro; (g)--C(O)H or--C(O)R 6 ;(h)--CO 2 H or--CO 2 R 6 ; (i)--SH,--S(O) n R 6,--S(O) m--OH,--S(O) m--OR 6,--O--S(O) m--R 6,--O--S(O) m OH or--O--S(O) m--OR. sup.6 ;(j)--Z. sup.4--NR 7 R 8 ; or (k)--Z 4--N(R 11--Z 5--NR 9 R 10 ; and the remaining symbols are as defined in the specification.